Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Announces Proposed Public Offering of Common Stock
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia
–Encouraging preliminary signs of biologic activity and a favorable safety profile are outcomes that are clinically relevant to patients – Enrollment ongoing in additional dose groups, which will include pediatric patients; interim data from these additional dose groups expected in 2H of 2020 –
View HTML
Toggle Summary AGTC to Host Conference Call and Webcast on January 23 at 8:00 am ET to Discuss Achromatopsia Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Agenda for R&D Day on January 28, 2020 in New York
Management and External Thought Leaders to Discuss Data from XLRP and ACHM Phase 1/2 Clinical Trials Webcast Scheduled from 7:30 am – 12:00 pm ET GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology
View HTML
Toggle Summary AGTC Reports Positive Six-Month Data from its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa
- Data suggest durable and meaningfully improvements in central visual sensitivity - Secondary data showed encouraging improvements in Best Corrected Visual Acuity - All patients dosed continue to demonstrate a favorable safety profile - Company plans to initiate pivotal trial by the end of 2020 -
View HTML
Toggle Summary AGTC to Host Conference Call and Webcast on January 9 at 8:00 am ET to Discuss X-Linked Retinitis Pigmentosa Interim Six-Month Data from the Dose Expansion Cohort of its Ongoing Phase 1/2 Clinical Trial
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Departure of Chief Medical Officer, Company on Track to Announce XLRP and ACHM Data in January 2020
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2019
Company to host R&D Day on January 28, 2020 , in New York GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies
View HTML
Toggle Summary AGTC to Host First Quarter Results Conference Call and Webcast on November 12, 2019
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Program and Reports Compelling Preclinical Data Supporting the Potential of its Dual-Vector Technology
- Simultaneous delivery of two optimized AAV vectors expands the therapeutic and commercial potential of AGTC's industry-leading AAV platform by enabling delivery of DNA encoding larger proteins - GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Applied Genetic
View HTML
Visionary science for life changing cures.